Nuvectis Pharma Inc (NVCT) outlined a bold late-stage pipeline with ciprocapan and NXP200, a cash runway into 2029, and multiple near-term catalysts despite FDA and competitive uncertainties.
Motley Fool Press Release.
WSW, NY, September 25th, 2026, FinanceWireThree months ago, Nuvectis Pharma (NASDAQ:NVCT) was an oncology developer anchored by a single early-stage program. Today it holds ex-China rights to the world's first
Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast li
This is the newest page. Registered accounts read further back.